Table 1

Percentage of patients achieving normalization1 of C-reactive protein levels and serum amyloid A protein levels

Variable

Canakinumab 10 mg

N = 28

Canakinumab 25 mg

N = 29

Canakinumab 50 mg

N = 28

Canakinumab 90 mg

N = 29

Canakinumab 150 mg

N = 27

Triamcinolone acetonide 40 mg

N = 56


CRP

Baseline

4 (14.3)

8 (27.6)

6 (21.4)

6 (20.7)

5 (18.5)

12 (21.4)

3 days post-dose

6 (22.2)

13 (46.4)

9 (34.6)

9 (32.1)

11 (44.0)

19 (35.8)

7 days post-dose

13 (46.4)

21 (72.4)*

16 (57.1)

19 (67.9)*

19 (70.4)*

23 (41.8)

4 weeks post-dose

21 (77.8)*

22 (78.6)*

20 (74.1)*

18 (64.3)

20 (74.1)*

27 (49.1)

8 weeks post-dose

17 (65.4)*

21 (75.0)*

17 (63.0)

21 (75.0)*

22 (81.5)*

23 (42.6)


SAA

Baseline

8 (28.6)

9 (32.1)

9 (32.1)

8 (27.6)

9 (33.3)

23 (44.2)

3 days post-dose

15 (57.7)

14 (50.0)

16 (57.1)

13 (46.4)

13 (48.1)

26 (48.1)

7 days post-dose

19 (67.9)

22 (75.9)*

19 (67.9)

21 (75.0)*

17 (65.4)

25 (47.2)

4 weeks post-dose

24 (88.9)*

24 (82.8)

19 (70.4)

20 (71.4)

18 (69.2)

34 (63.0)

8 weeks post-dose

18 (69.2)

21 (80.8)

18 (69.2)

19 (70.4)

20 (74.1)

30 (57.7)


*P < 0.05 vs triamcinolone acetonide 40 mg.

1Upper limit of normal: 3 mg/L for CRP, 6.7 mg/L for SAA.

CRP, C-reactive protein; SAA, serum amyloid A protein.

Schlesinger et al. Arthritis Research & Therapy 2011 13:R53   doi:10.1186/ar3297

Open Data